Pursuant to public comments filed by interested parties regarding the recent business impact analysis to drug compounding rules 4729-16-01, 4729-16-04 and 4729-16-13, the State of Ohio Board of Pharmacy (SOBP) submitted a formal response to the Common Sense Initiative (CSI) on August 25. The CSI is an agency created by the Kasich Administration to review proposed rules relative to their business impact.
After receiving another round of comments expressing concerns from physician and prescriber organizations, the SOBP further amended rules at their August 9 meeting to address those comments and as a result most practices now won’t have to invest in expensive equipment to be in compliance. Under the current rule draft, Ohio administrative rules would be no stricter than federal rules and that is a big improvement over rules originally filed.
Great job by Ann Spicer and the OAFP staff for promoting the OAFP views on this issue!